I read with great interest your article on racial disparities in breast cancer detection, treatment, and outcomes (1). My comments below are aimed at specifically addressing the disparities in the utilization of adjuvant treatment. The simulation model applied in this study claims to predict the differential impact of adjuvant treatment on breast cancer mortality. But the increase in mortality ...

BACKGROUND As the toxicity associated with the α-GalCer-pulsed dendritic cell (DC) therapy could be considered to be negligible, its addition to postoperative adjuvant chemotherapy would be expected to greatly improve the therapeutic effect, and could result in prolonged survival. The aim of the present study is to compare the therapeutic efficacy of alpha-galactosylceramide-pulsed DC therapy i...

The 1992 metaanalysis of adjuvant therapies after surgery in early breast cancer summarizes the most extensively studied of all cancer treatments via randomized controlled trials. This study found overall benefits with use of adjuvant therapies, and their expanded use outside the clinical trial setting was assumed to be effective and implied to be cost effective. Thus, the primary remaining que...

PURPOSE To update the ASCO adjuvant endocrine therapy guideline based on emerging data concerning the benefits and risks of ovarian suppression in addition to standard adjuvant therapy in premenopausal women with estrogen receptor-positive breast cancer. METHODS ASCO convened an Update Panel and conducted a systematic review of randomized clinical trials investigating ovarian suppression. R...

Debate continues surrounding the indications for adjuvant and salvage radiotherapy as the published randomized trials have only addressed adjuvant treatment. Salvage radiotherapy has been advocated to limit significant toxicity to patients that would not have benefited from immediate adjuvant radiotherapy. The American Urological Association and American Society for Radiation Oncology guideline...

Screening for prostate cancer by determining serum prostate-specific antigen (PSA) levels has resulted in a stage migration such that patients with high-risk disease are more likely to be candidates for curative local therapy. By combining serum PSA, clinical stage, and biopsy information--both Gleason score and volume of tumor in the biopsy cores--specimen pathologic stage and patient biochemi...

The treatment of breast cancer has progressed substantially over the past 15 years. Data from randomized adjuvant trials have shown that the risk of disease recurrence and death is significantly reduced when adjuvant chemotherapy and/or hormonal therapy is added to treatment. As new strategies are incorporated, one of the continued controversies in patient management is whether adjuvant anthrac...

Cancer is one of the leading causes morbidity in globe, with more than half patients reporting pain as a result disease. By reducing cancer-related pain, dance has potential to redefine life independently their cure prognosis. This review investigated benefits adjuvant, non-pharmacological therapy for cancer treatment. To identify studies related this topic, we searched Cochrane Library, PUBMED...

Herein we report a case of primary leiomyosarcoma of testis, which was believed to originate from normal testicular structures.  It contained smooth muscle cells, blood vessels and contractile cells of the seminiferous tubules.  No evidence of tumor spread was found.Treatment consisted of orchiectomy with high ligation of the spermatic cord.  The patient received no adjuvant therapy and there w...

BACKGROUND There is no consensus on the need for adjuvant chemotherapy for patients with pathological residual invasive breast cancer (non-pCR) after neoadjuvant chemotherapy (NAC). We evaluated the tolerability and safety of tegafur-uracil (UFT) as adjuvant chemotherapy for patients with human epidermal growth factor receptor 2-negative breast cancer that resulted in non-pCR after NAC. PATIE...